A double-blind placebo controlled trial of diltiazem in Duchenne dystrophy. 1988

W Pernice, and R Beckmann, and U P Ketelsen, and M Frey, and B Schmidt-Redemann, and K P Haap, and R Roehren, and M Sauer
Abteilung Pädiatrische Muskelerkrankungen, Universitäts-Kinderklinik, Freiburg.

The role of calcium accumulation in the pathogenesis of Duchenne muscular dystrophy (DMD) has already been discussed. Several trials with different calcium-blocking drugs have revealed no clinical benefit. In addition, the present study includes histological investigations and computer tomography to verify therapeutic effects. In a randomized placebo-controlled double-blind study, 13 DMD patients aged from 3-10 years (mean, 7 years) were treated with 5 mg/kg diltiazem daily for 1 year. Compared with before therapy, the number of calcium-positive muscular fibres was remarkably reduced in the treated DMD patients, but not in the placebo group. The evaluation of all other biochemical and clinical parameters revealed no significant effects of the diltiazem therapy. The muscular X-ray density measured by computer tomography decreased under treatment. After the evaluation of the double-blind study, the code was broken. Therapy, however, was continued in the treated group and started in the placebo group. After 3 years of diltiazem therapy the clinical status of all 26 patients of the study and 20 additional DMD patients who were treated with diltiazem was compared with 46 untreated DMD patients of the same age and stage in our department. No obvious clinical benefit of diltiazem therapy could be observed.

UI MeSH Term Description Entries
D007473 Ion Channels Gated, ion-selective glycoproteins that traverse membranes. The stimulus for ION CHANNEL GATING can be due to a variety of stimuli such as LIGANDS, a TRANSMEMBRANE POTENTIAL DIFFERENCE, mechanical deformation or through INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS. Membrane Channels,Ion Channel,Ionic Channel,Ionic Channels,Membrane Channel,Channel, Ion,Channel, Ionic,Channel, Membrane,Channels, Ion,Channels, Ionic,Channels, Membrane
D009132 Muscles Contractile tissue that produces movement in animals. Muscle Tissue,Muscle,Muscle Tissues,Tissue, Muscle,Tissues, Muscle
D009136 Muscular Dystrophies A heterogeneous group of inherited MYOPATHIES, characterized by wasting and weakness of the SKELETAL MUSCLE. They are categorized by the sites of MUSCLE WEAKNESS; AGE OF ONSET; and INHERITANCE PATTERNS. Muscular Dystrophy,Myodystrophica,Myodystrophy,Dystrophies, Muscular,Dystrophy, Muscular,Myodystrophicas,Myodystrophies
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004110 Diltiazem A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions. Aldizem,CRD-401,Cardil,Cardizem,Dilacor,Dilacor XR,Dilren,Diltiazem Hydrochloride,Diltiazem Malate,Dilzem,Tiazac,CRD 401,CRD401
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked

Related Publications

W Pernice, and R Beckmann, and U P Ketelsen, and M Frey, and B Schmidt-Redemann, and K P Haap, and R Roehren, and M Sauer
January 1991, Wiener klinische Wochenschrift,
W Pernice, and R Beckmann, and U P Ketelsen, and M Frey, and B Schmidt-Redemann, and K P Haap, and R Roehren, and M Sauer
February 2015, The Lancet. Neurology,
W Pernice, and R Beckmann, and U P Ketelsen, and M Frey, and B Schmidt-Redemann, and K P Haap, and R Roehren, and M Sauer
November 2010, The Lancet. Neurology,
W Pernice, and R Beckmann, and U P Ketelsen, and M Frey, and B Schmidt-Redemann, and K P Haap, and R Roehren, and M Sauer
August 1985, The Journal of rheumatology,
W Pernice, and R Beckmann, and U P Ketelsen, and M Frey, and B Schmidt-Redemann, and K P Haap, and R Roehren, and M Sauer
January 1987, Muscle & nerve,
W Pernice, and R Beckmann, and U P Ketelsen, and M Frey, and B Schmidt-Redemann, and K P Haap, and R Roehren, and M Sauer
October 2001, Neurology,
W Pernice, and R Beckmann, and U P Ketelsen, and M Frey, and B Schmidt-Redemann, and K P Haap, and R Roehren, and M Sauer
November 2019, Trials,
W Pernice, and R Beckmann, and U P Ketelsen, and M Frey, and B Schmidt-Redemann, and K P Haap, and R Roehren, and M Sauer
September 1984, Muscle & nerve,
W Pernice, and R Beckmann, and U P Ketelsen, and M Frey, and B Schmidt-Redemann, and K P Haap, and R Roehren, and M Sauer
December 1990, Muscle & nerve,
W Pernice, and R Beckmann, and U P Ketelsen, and M Frey, and B Schmidt-Redemann, and K P Haap, and R Roehren, and M Sauer
August 1989, Pain,
Copied contents to your clipboard!